Akums Drugs and Pharmaceuticals Limited (AKUMS) Price & Analysis

Compare

4 Followers

AKUMS Stock Chart & Stats

₹420.10

₹13.30(2.17%)

At close: Jan 08 4:00 PM EST

₹420.10

₹13.30(2.17%)

Day’s Range― - ―

52-Week Range₹407.40 - ₹620.00

Previous CloseN/A

Volume56.90K

Average Volume (3M)11.50K

Market Cap

₹70.93B

Enterprise Value₹70.61B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)21.7

Beta1.53

Next Earnings

Jun 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.33

Shares Outstanding157,393,980

10 Day Avg. Volume12,021

30 Day Avg. Volume11,497

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)2.32

Price to Sales (P/S)1.74

P/FCF Ratio36.67

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹600.00

Price Target Upside42.82% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue & Margin ImprovementSustained top-line growth paired with materially higher gross and restored net margins supports structural profitability. Improved margins indicate better pricing, product mix or cost control, which underpins durable cash flow generation and reinvestment capacity over the next several quarters.

Marked Deleveraging And Stronger Equity BaseA dramatic cut in leverage materially reduces financial risk and interest burden, improving resilience to shocks and enabling strategic investments or opportunistic M&A. Higher ROE alongside lower debt suggests the firm is earning reasonable returns while strengthening its capital structure.

Healthy Cash Generation And FCF GrowthConsistent operating cash flow and positive free cash flow growth indicate effective cash conversion and prudent working-capital management. A strong OCF-to-net-income ratio suggests earnings quality and provides durable funding for capex, debt reduction, R&D or strategic initiatives.

Bears Say

EBIT Margin DeteriorationA falling EBIT margin signals rising operating costs or weaker operating leverage versus revenue growth. If persistent, lower operating profitability can erode the firm's ability to fund growth internally and reduce resilience to margin pressure in competitive pharmaceutical markets.

Year-over-year OCF DeclineA decline in operating cash flow, even from a high base, may reflect working-capital build, one-off receipts in the prior year, or margin timing. Continued OCF erosion would constrain free cash flow availability for reinvestment, debt servicing or shareholder returns over the medium term.

No Dividend YieldNot returning cash via dividends reduces direct shareholder income and can signal prioritization of reinvestment or balance-sheet repair. For investors seeking yield or disciplined capital allocation, the lack of a dividend is a structural drawback unless retained cash demonstrably funds higher-return uses.

Akums Drugs and Pharmaceuticals Limited News

Akums Closes Trading Window Ahead of Q3 FY2025 Unaudited Results

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an announcement. Akums Drugs and Pharmaceuticals Limited has...

2M ago

AKUMS

Akums Secures Patent for Innovative GERD Treatment

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has shared an announcement. Akums Drugs and Pharmaceuticals Limited has...

4M ago

AKUMS

Akums Drugs Expands with New Subsidiary in Malta

The latest update is out from Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ). Akums Drugs and Pharmaceuticals...

4M ago

AKUMS

Akums Expands with New Joint Venture in Zambia

Akums Drugs and Pharmaceuticals Limited ( ($IN:AKUMS) ) has issued an update. Akums Drugs and Pharmaceuticals Limited has...

4M ago

AKUMS

AKUMS FAQ

What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?

Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹407.40 and its highest was ₹620.00 in the past 12 months.

What is Akums Drugs and Pharmaceuticals Limited’s market cap?

Akums Drugs and Pharmaceuticals Limited’s market cap is ₹70.93B.

When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?

Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Jun 01, 2026 which is in 104 days.

How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?

Akums Drugs and Pharmaceuticals Limited released its earnings results on Feb 05, 2026. The company reported ₹4.332 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.332.

Is Akums Drugs and Pharmaceuticals Limited overvalued?

According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Akums Drugs and Pharmaceuticals Limited pay dividends?

Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.

What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?

Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?

Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.

What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?

Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹4.332 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.789%.

Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:AKUMS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited (AKUMS) is a leading Indian pharmaceutical manufacturer and exporter, specializing in the production of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). Established in 2004, the company primarily operates in the sectors of prescription medicines, over-the-counter (OTC) products, and nutraceuticals. AKUMS is known for its commitment to quality and innovation, offering a diverse portfolio that includes formulations across various therapeutic segments such as cardiology, gynecology, and dermatology.

Akums Drugs and Pharmaceuticals Limited (AKUMS) Earnings & Revenues

Historic Earnings Reports

AKUMS Stock 12 Month Forecast

Average Price Target

₹600.00

▲(42.82% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"423":"₹423","868":"₹868","534.25":"₹534.3","645.5":"₹645.5","756.75":"₹756.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹600.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[423,534.25,645.5,756.75,868],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,450,462.5,475,487.5,500,512.5,525,537.5,550,562.5,575,587.5,{"y":600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,450,462.5,475,487.5,500,512.5,525,537.5,550,562.5,575,587.5,{"y":600,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,437.5,450,462.5,475,487.5,500,512.5,525,537.5,550,562.5,575,587.5,{"y":600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":791.7,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":791.7,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":832.65,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":867.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":841.1,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":617.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >